Much of the population experiences disordered breathing at night, explained Krishna M. Sundar, MD, clinical professor, Pulmonary Division, Department of Medicine, and medical director, Sleep-Wake Center, University of Utah.
Much of the population experiences disordered breathing at night, but more people are familiar with obstructive sleep apnea than they are central sleep apnea, the latter of which is often seen in patients with heart disease, noted Krishna M. Sundar, MD, clinical professor, Pulmonary Division, Department of Medicine, and medical director, Sleep-Wake Center, University of Utah.
Transcript
How do obstructive sleep apnea and central sleep apnea differ?
So these disorders affect breathing at night, which a significant proportion of the population experiences. Most folks are familiar with obstructive sleep apnea, which is a disorder characterized by collapsing of the upper airway, which is the portion of the airway just behind your throat, during sleep, and that happens because the muscles which keep this passage relatively open, they relax at night when you’re sleeping on your back. There tends to be narrowing, and each time you breathe in, you’re sucking air. You create a negative pressure that causes the passage to collapse with the inhaled airflow. So that's obstructive sleep apnea. And that's characterized with snoring and pauses in breathing and often gasping awakenings that many people are familiar with.
The other disorder is something called central sleep apnea. So when we talk about pauses in breathing, it can either happen due to obstruction, which happens in obstructive sleep apnea, or because there can be a pause in breathing, because the breathing center—which is located in the brainstem, or the lower portion of the brain—so that breathing center fires impulses, which drive each breath, basically. And in central sleep apnea, because the control of breathing changes during sleep, there are pauses in breathing because this respiratory generator is not firing the necessary impulses in a periodic manner as happens during wakefulness.
And that's another disorder, which probably not as prevalent as obstructive sleep apnea, is often seen in disorders such as heart disease, heart failure, particularly; in neurologic conditions; and people that are on opiates. The opiate epidemic, this has become a matter of great interest because it appears that a substantial proportion of those who die from opioid overdose, they die a respiratory death in which there is actually a stoppage of breathing.
So occurrence of central apnea is typically especially during sleep, may be a marker. Again, we don't know; that’s yet to be proven, but it may be indicative of susceptibility to opiate-related respiratory depression. But more than that, central sleep apnea can be seen in a variety of conditions. One of the unique aspects of central sleep apnea is often tends to occur in a setting of obstructive sleep apnea.
So both of these disorders, especially when central apnea occurs, it occurs in the background of obstructive sleep apnea, and to separate out, and the relevance of both and what is driving the other, requires some understanding of what we call the pathophysiology of these problems.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
Laundromats as a New Frontier in Community Health, Medicaid Outreach
May 29th 2025Lindsey Leininger, PhD, and Allister Chang, MPA, highlight the potential of laundromats as accessible, community-based settings to support Medicaid outreach, foster trust, and connect families with essential health and social services.
Listen
ICS Use Tied to Fewer Exacerbations in Patients With Bronchiectasis and Elevated Blood Eosinophils
June 6th 2025Inhaled corticosteroid (ICS) use was common among patients with bronchiectasis and was associated with reduced exacerbations and hospitalizations in those with elevated blood eosinophil counts.
Read More
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More